{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:55:21Z","timestamp":1794099321897,"version":"4.8.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Gastroenterology"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1111\/j.1572-0241.2008.01818.x","type":"journal-article","created":{"date-parts":[[2008,4,4]],"date-time":"2008-04-04T13:03:15Z","timestamp":1207314195000},"page":"815-819","source":"Crossref","is-referenced-by-count":32,"title":["Balancing Drug Risk and Benefit: Toward Refining the Process of FDA Decisions Affecting Patient Care"],"prefix":"10.14309","volume":"103","author":[{"given":"Lawrence R.","family":"Schiller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"b1_347","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.21.2647"},{"key":"b2_348","unstructured":"2. Wolfe S. How independent is the FDA? Available at: http:\/\/www.pbs.org\/wgbh\/pages\/frontline\/ shows\/pres-cription\/hazard\/independent.html. Accessed November 17, 2007."},{"key":"b3_349","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp078041"},{"key":"b4_350","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3122\/jabfm.17.2.142","volume":"17","author":"Deyo RA","year":"2004","journal-title":"J Am Board Fam Pract"},{"key":"b5_351","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/jnci\/97.12.872","volume":"97","author":"Zielinski SL","year":"2005","journal-title":"JNCI J Natl Cancer Inst"},{"key":"b6_352","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp078157"},{"key":"b7_353","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.18.1938"},{"key":"b8_354","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.06.010"},{"key":"b9_355","unstructured":"9. Questions and Answers: Lotronex\n                      TM\n                      Tablets, alosetron hydrochloride. Available at: http:\/\/www.fda.gov\/Cder\/drug\/infopage\/lotronex\/lotronex-qa.htm. Accessed October 30, 2007."},{"key":"b10_356","unstructured":"10. Lotronex Tablets (alosetron hydrochloride): Questions and Answers. Available at: http:\/\/www.fda.gov\/Cder\/drug\/infopage\/lotronex\/lotronex-qa_0602.htm. Accessed October 28, 2007."},{"key":"b11_357","unstructured":"11. Zelnorm\n                      TM\n                      (tegaserod maleate) tablets: Prescribing information. Available at: http:\/\/www.fda.gov\/cder\/foi\/label\/ 2002\/ 21200lbl.pdf. Accessed October 28, 2007."},{"key":"b12_358","unstructured":"12. Novartis \"Dear Healthcare Provider\" letter, dated April 26, 2004. Available at: http:\/\/www.fda.gov\/medwatch\/SAFETY\/2004\/zelnorm_deardoc_042604.pdf. Accessed October 28, 2007."},{"key":"b13_359","unstructured":"13. FDA Announces Discontinued Marketing of GI Drug, Zelnorm, for Safety Reasons . Available at: http:\/\/www.fda.gov\/bbs\/topics\/NEWS\/2007\/NEW01597.html. Accessed October 28, 2007."},{"key":"b14_360","unstructured":"14. DA Improvements in Drug Safety Monitoring . Available at: http:\/\/www.fda.gov\/oc\/factsheets\/drugsafety.html. Accessed November 17, 2007."},{"key":"b15_361","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.5.526.33351"},{"key":"b16_362","unstructured":"16. FDA Permits Restricted Use of Zelnorm for Qualifying Patients . Available at: http:\/\/www.fda.gov\/bbs\/topics\/NEWS\/2007\/NEW01673.html. Accessed October 28, 2007."},{"key":"b17_363","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00045-4"},{"key":"b18_364","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7270.1183"},{"key":"b19_365","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2007.06.006"},{"key":"b20_366","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20948"},{"key":"b21_367","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072761"},{"key":"b22_368","unstructured":"22. FDA Adds Boxed Warning for Heart-related Risks to Anti-Diabetes Drug Avandia . Available at: http:\/\/www.fda.gov\/bbs\/topics\/NEWS\/2007\/NEW01743.html. Accessed November 17, 2007."},{"key":"b23_369","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.F.00952"},{"key":"b24_370","unstructured":"24. Food and Drug Administration Amendments Act of 2007 . Public Law 110-85-September 27, 2007. 121 Stat. 823-978. Available at: http:\/\/thomas.loc.gov\/cgi-bin\/bdquery\/z?d110:h.r.03580: Accessed January 1, 2008."},{"key":"b25_371","unstructured":"25. Swann JP. History of the FDA . Available at: http:\/\/www.fda.gov\/oc\/history\/historyoffda\/default.htm. Accessed November 17, 2007."},{"key":"b26_372","volume-title":"Building a 21st century FDA: Proposals to improve drug safety and innovation","year":"2007"},{"key":"b27_373","volume-title":"The future of drug safety: Promoting and protecting the health of the public","author":"Baciu A","year":"2007"}],"container-title":["The American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000434-200804000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:43:33Z","timestamp":1786542213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-200804000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1572-0241.2008.01818.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1572-0241.2008.01818.x","relation":{},"ISSN":["0002-9270","1572-0241"],"issn-type":[{"value":"0002-9270","type":"print"},{"value":"1572-0241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}